Platinum rechallenge in the era of immune checkpoint inhibitor in locally advanced/metastatic urothelial carcinoma: Multicenter retrospective study

被引：0
|
作者：
Kim, E. [1 ]
Kim, J. H. [2 ]
Chu, J. [3 ]
Lee, Y-G. [1 ]
Im, H-S. [4 ]
机构：
[1] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Hematol & Oncol, Sch Med, Seoul, South Korea
[2] Korea Univ, Anam Hosp, Dept Oncol Hematol, Seoul, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Pathol, Sch Med, Seoul, South Korea
[4] Ulsan Univ Hosp, Dept Hematol & Oncol, Ulsan, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1033
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2384P
引用
收藏
页码：S1214 / S1214
页数：1
相关论文
共 50 条
  • [21] Urothelial carcinoma in the era of immune checkpoint inhibitors
    Khalife, Nadine
    Chahine, Claude
    Kordahi, Manal
    Felefly, Tony
    Kourie, Hampig Raphael
    Saleh, Khalil
    IMMUNOTHERAPY, 2021, 13 (11) : 953 - 964
  • [22] Immune checkpoint inhibition in metastatic urothelial carcinoma
    Bedke, Jens
    Todenhoefer, Tilman
    Stenzl, Arnulf
    AKTUELLE UROLOGIE, 2018, 49 (02) : 178 - 186
  • [23] Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-A Retrospective Multicenter Analysis
    Riedel, Felix
    Muenker, Mara
    Roghmann, Florian
    Breyer, Johannes
    Schnabel, Marco J.
    Burger, Maximilian
    Sikic, Danijel
    Buettner, Thomas
    Ritter, Manuel
    Hiller, Kiriaki
    Wezel, Felix
    Bolenz, Christian
    Zengerling, Friedemann
    CANCERS, 2022, 14 (12)
  • [24] Cohort study of metastatic and unresectable, locally advanced urothelial carcinoma
    Rexer, Heidrun
    Schnabel, Marco J.
    Retz, Margitta
    AKTUELLE UROLOGIE, 2024, 55 (03)
  • [25] Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
    Hong, Joohyun
    Sung, Hyun Hwan
    Jeong, Byong Chang
    Park, Se Hoon
    BIOMEDICINES, 2022, 10 (08)
  • [26] Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
    Loriot, Y.
    Necchi, A.
    Park, S. H.
    Garcia-Donas, J.
    Huddart, R.
    Burgess, E.
    Fleming, M.
    Rezazadeh, A.
    Mellado, B.
    Varlamov, S.
    Joshi, M.
    Duran, I.
    Tagawa, S. T.
    Zakharia, Y.
    Zhong, B.
    Stuyckens, K.
    Santiago-Walker, A.
    De Porre, P.
    O'Hagan, A.
    Avadhani, A.
    Siefker-Radtke, A. O.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (04): : 338 - 348
  • [27] Erdafitinib for locally advanced or metastatic urothelial carcinoma
    Siefker-Radtke, Arlene O.
    Loriot, Yohann
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (11) : 824 - 825
  • [28] Avelumab in locally advanced or metastatic urothelial carcinoma
    Jackson-Spence, Francesca
    Szabados, Bernadett
    Toms, Charlotte
    Yang, Yu-Hsuen
    Sng, Christopher
    Powles, Thomas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (02) : 135 - 140
  • [29] TAS0313 plus Pembrolizumab for Post-Chemotherapy Immune Checkpoint Inhibitor-Naïve Locally Advanced or Metastatic Urothelial Carcinoma
    Nishiyama, Hiroyuki
    Yonese, Junji
    Kawahara, Takashi
    Matsumoto, Ryuji
    Miyake, Hideaki
    Matsubara, Nobuaki
    Uemura, Hiroji
    Eto, Masatoshi
    Azuma, Haruhito
    Obara, Wataru
    Terai, Akito
    Fukasawa, Satoshi
    Suekane, Shigetaka
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (04) : 532 - 540
  • [30] The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study
    Iinuma, Koji
    Yamada, Toyohiro
    Kameyama, Koji
    Taniguchi, Tomoki
    Kawada, Kei
    Ishida, Takashi
    Nagai, Shingo
    Enomoto, Torai
    Ueda, Shota
    Takagi, Kimiaki
    Kawase, Makoto
    Takeuchi, Shinichi
    Kawase, Kota
    Kato, Daiki
    Takai, Manabu
    Nakane, Keita
    Koie, Takuya
    CANCERS, 2023, 15 (03)
12345